Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...
DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...
Shares of DexCom Inc. DXCM shed 1.40% to $73.02 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.81% to 7,543.64 and the Dow ...
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
Shares of DexCom Inc. DXCM advanced 3.47% to $71.25 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX remaining mostly unchanged at 7, ...
The FDA’s indication expansion for Dexcom’s Stelo makes it the first over the counter CGM available for children, including those with diabetes.
20hon MSN
Influencers are hopping on a surprising wearable trend that requires a needle — do you need one?
Influencers have found their latest wellness obsession — and, once again, diabetics got there first. First, came GLP-1 drugs.
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible ...
If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...
The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of ...
Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results